Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage
Stroke · 2023-12 · 54 (12) · 3173-3181
DOI: 10.1161/strokeaha.123.036886 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stroke, 2023-12. Verfasst von Rustam Al-Shahi Salman und 1 weiteren Autor:innen. Beteiligte Einrichtung: The University of Edinburgh, Royal Infirmary of Edinburgh, United Kingdom (R.A.-S.S.). Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Stroke. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: British Heart Foundation, Medical Research Council.
Themen: Schlaganfall
Abstract (Originalsprache)
This focused update about antiplatelet agents to reduce the high risk of major adverse cardiovascular events after stroke due to spontaneous (nontraumatic) intracerebral hemorrhage (ICH) complements earlier updates about blood pressure-lowering, lipid-lowering, and oral anticoagulation or left atrial appendage occlusion for atrial fibrillation after ICH. When used for secondary prevention in people without ICH, antiplatelet agents reduce the risk of major adverse cardiovascular event (rate ratio, 0.81 [95% CI, 0.75–0.87]) and might increase the risk of ICH (rate ratio, 1.67 [95% CI, 0.97–2.90]). Before 2019, guidance for clinical decisions about antiplatelet agent use after ICH has focused on estimating patients’ predicted absolute risks and severities of ischemic and hemorrhagic major adverse cardiovascular event and applying the known effects of these drugs in people without ICH to estimate whether individual ICH survivors in clinical practice might be helped or harmed by antiplatelet agents. In 2019, the main results of the RESTART (Restart or Stop Antithrombotics Randomized Trial) randomized controlled trial including 537 survivors of ICH associated with antithrombotic drug use showed, counterintuitively, that antiplatelet agents might not increase the risk of recurrent ICH compared to antiplatelet agent avoidance over 2 years of follow-up (12/268 [4%] versus 23/268 [9%]; adjusted hazard ratio, 0.51 [95% CI, 0.25–1.03]; P =0.060). Guidelines in the United States, Canada, China, and the United Kingdom and Ireland have classified the level of evidence as B and indicated that antiplatelet agents may be considered/reasonable after ICH associated with antithrombotic agent use. Three subsequent clinical trials have recruited another 174 participants with ICH, but they will not be sufficient to determine the effects of antiplatelet therapy on all major adverse cardiovascular events reliably when pooled with RESTART. Therefore, ASPIRING (Antiplatelet Secondary Prevention International Randomized Study After Intracerebral Hemorrhage) aims to recruit 4148 ICH survivors to determine the effects of antiplatelet agents after ICH definitively overall and in subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Edinburgh, Royal Infirmary of Edinburgh, United Kingdom (R.A.-S.S.).
- Massachusetts General Hospital and Harvard Medical School, Boston (S.M.G.).
ORCID-Profile: Rustam Al-Shahi Salman, Steven M Greenberg
Förderung
- British Heart Foundation
- Medical Research Council
Zitieren
APA
Al-Shahi Salman, R., & Greenberg, S. M. (2023). Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage. Stroke, 54(12), 3173-3181. https://doi.org/10.1161/strokeaha.123.036886
Vancouver
Al-Shahi Salman R, Greenberg SM. Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage. Stroke. 2023;54(12):3173-3181. doi:10.1161/strokeaha.123.036886
BibTeX
@article{AlShahiSalman2023,
author = {Al-Shahi Salman, Rustam and Greenberg, Steven M},
title = {Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage},
journal = {Stroke},
year = {2023},
volume = {54},
number = {12},
pages = {3173--3181},
doi = {10.1161/strokeaha.123.036886}
}
EUVIMED